Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: A study by the European Group for Blood and Marrow Transplantation

Clinical Infectious Diseases

Volumn 59, Issue 4, 2014, Pages 473-481

  Ljungman, Per ^a,b   Brand, Ronald ^c   Hoek, Jennifer ^c   De La Camara, Rafael ^d   Cordonnier, Catherine ^e   Einsele, Hermann ^f   Styczynski, Jan ^g   Ward, Katherine N ^h   Cesaro, Simone ⁱ  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HENRI MONDOR HOSPITAL   (France)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ Paediatric Haematology Oncology   (Italy)

Author keywords

CMV; Donor; Recipient; Serological status; Stem cell transplant

Indexed keywords

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; DONOR; FEMALE; GRAFT RECIPIENT; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SEROLOGY; SIBLING; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905043824     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu364     Document Type: Article

References (35)

1. Goodrich J, Bowden R, Fisher L, Keller C, Schoch G, Meyers J. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-8.
2. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749-53.
3. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118: 179-84.
4. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-20.
5. Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21: 597-605.
6. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358-64.
7. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240-5.
8. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273-82.
9. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-88.
10. Grob JP, Grundy JE, Prentice HG, et al. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet 1987; 1: 774-6.
11. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043-51.
12. Ljungman P, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serological status influences the outcome of CMV seropositive recipients after unrelated donor stem cell transplantation: an EBMT Megafile analysis. Blood 2003; 102: 4255-60.
13. Ljungman P, Brand R. Factors influencing cytomegalovirus seropositivity in stem cell transplant patients and donors. Haematologica 2007; 92: 1139-42.
14. Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66: 1330-4.
15. Meyers J, Flournoy N, Thomas E. Nonbacterial pneumonia after allogeneic marrow transplantation: review of ten years' experience. Rev Infect Dis 1982; 4: 1119-31.
16. Zaia JA, Forman SJ. Cytomegalovirus infection in the bone marrow transplant recipient. Infect Dis Clin North Am 1995; 9: 879-900.
17. Bacigalupo A, Tedone E, Sanna MA, et al. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Haematologica 1992; 77: 507-13.
18. Takenaka K, Gondo H, Tanimoto K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant 1997; 19: 241-8.
19. Craddock C, Szydlo RM, Dazzi F, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 2001; 112: 228-36.
20. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 2011; 25: 151-69.
21. Schmidt-Hieber M, Labopin M, Beelen D, et al. CMV serostatus has still an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 2013; 122: 3359-64.
22. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314: 1006-10.
23. Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013; 19: 117-22.
24. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-50.
25. Avetisyan G, Aschan J, Hagglund H, Ringden O, Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 2007; 40: 865-9.
26. Ganepola S, Gentilini C, Hilbers U, et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 293-9.
27. Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008; 93: 248-56.
28. Moins-Teisserenc H, Busson M, Scieux C, et al. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J Infect Dis 2008; 198: 818-26.
29. Zhou W, Longmate J, Lacey SF, et al. Impact of donor CMV-status on viral infection and reconstitution of multi-function CMV-specific T-cells in CMV-positive transplant recipients. Blood 2009; 113: 6465-76.
30. Lin TS, Zahrieh D, Weller E, Alyea EP, Antin JH, Soiffer RJ. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation. Transplantation 2002; 74: 49-54.
31. Ozdemir E, Saliba R, Champlin R, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007; 40: 125-36.
32. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006; 91: 78-83.
33. Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110: 490-500.
34. Maris M, Boeckh M, Storer B, et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003; 31: 941-52.
35. Nakamae H, Kirby KA, Sandmaier BM, et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15: 694-703.